Summary:
- Maia Biotechnology, a clinical-stage biopharmaceutical company, has had an abstract selected for a poster presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
- The abstract focuses on the company's lead product candidate, THIO, which is being developed for the treatment of various types of cancer.
- This selection for the ASCO conference is a significant milestone for Maia Biotechnology, as it showcases the potential of their research and development efforts in the field of oncology.